Additionally, patients should be informed that insurance coverage for compounded medications is often limited or unavailable, and that once brand-name products are no longer in shortage, continued use of compounded versions may not be appropriate or legal under FDA regulations
Average A1C of 8.1% indicated glucose levels substantially above target
Peptide or compound Primary category What researchers study Status context Semaglutide GLP-1 / metabolic Appetite, glucose, and cardiometabolic signaling FDA-approved products exist for specific indications Tirzepatide GIP/GLP-1 / metabolic Appetite, glucose, and metabolic signaling FDA-approved products exist for specific indications Retatrutide Triple agonist / metabolic GLP-1, GIP, and glucagon receptor signaling Investigational BPC-157 Tissue-repair research Gastrointestinal, tendon, and angiogenesis pathways Research-only
If a peptide was used recently, it is generally more likely to be detected , especially in specialized testing environments